Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

EP: 1.Evolving Horizons in HER2-Positive Breast Cancer Care

EP: 2.Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program

EP: 3.Integrating Emerging DESTINY-Breast Data Into HER2+ Treatment Strategies

EP: 4.Interpreting Key Data From KATHERINE, HER2CLIMB-05, and PATINA

EP: 5.Defining Success in Metastatic Breast Cancer Trial Design

EP: 6.Personalized Selection of HER2+ Breast Cancer Therapies

EP: 7.Navigating ADC Use and Sequencing in HER2+ Breast Cancer

EP: 8.Balancing Efficacy and Safety in HER2+ Breast Cancer Trials

EP: 9.Exploring Off-Label HER2-Targeted Therapy in Early Breast Cancer

EP: 10.Optimizing Safety and Adherence in HER2-Targeted Therapy Through Nursing and AE Management

Now Viewing

EP: 11.Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

EP: 12.Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

Gaps in care coordination remain a challenge for HER2-positive breast cancer patients, particularly in communication between oncologists, pharmacists, and payers. Rapidly evolving HER2-targeted therapies can outpace guideline updates from organizations like NCCN and ASCO, leaving clinicians navigating complex treatment decisions with limited consensus. Financial toxicity is a growing concern, encompassing the economic burden of treatment costs, copayments, and ancillary expenses that can impact adherence and quality of life. Addressing these issues requires proactive strategies, including early engagement of financial counseling, assistance programs, and transparent discussions about treatment costs. System-level interventions—such as aligning coverage policies with emerging evidence and supporting multidisciplinary care teams—can help reduce both clinical and financial barriers. Optimizing coordination and mitigating financial strain are essential to ensure equitable access and maximize outcomes for patient